Skip to Content
Biotechnology and health

Up to 40 percent of DNA results from consumer genetic tests might be bogus

March 27, 2018

A new study has found that direct-to-consumer genetic tests, like those marketed by 23andMe, Ancestry.com, Family Tree DNA, and MyHeritage, can be used to obtain innacurate results.

Data dump: Most of these tests use a technique called genotyping to provide information about a person’s ancestry, risk of developing certain disorders, or status as a carrier of specific diseases. Some companies also make the raw genotyping data available to customers upon request. People can then take that data to third-party companies to interpret for a fee.

Lost in interpretation: Scientists at Ambry Genetics, a diagnostics company that also interprets data from consumer DNA tests, looked at this raw genotyping data from 49 people. They found that 40 percent of the variants noted in the raw data were false positives—that is, they indicated that a particular genetic variant was present when it wasn’t. Most of the false-positive calls were of cancer-linked genes. In eight instances, third-party interpretation services misunderstood the variants present. 

Buyer beware: Unlike clinical genetic tests that require a physician’s sign-off, direct-to-consumer tests are not meant to provide a diagnosis, and they offer risk information for only a limited number of conditions. If a consumer DNA kit uncovers a surprising or noteworthy genetic variant, the authors advise people to seek out doctor-ordered genetic tests to confirm the results.  

Deep Dive

Biotechnology and health

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

The quest to legitimize longevity medicine

Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.

There is a new most expensive drug in the world. Price tag: $4.25 million

But will the latest gene therapy suffer the curse of the costliest drug?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.